The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Afatinib Dimaleate Market Research Report 2024
Synopsis
Afatinib dimaleate is an oral molecular targeted drug developed and produced by Boehringer Ingelheim, Germany. It is a TKIs with strong and irreversible dual inhibitory effect on EGFR and HER2, and was approved by THE US FDA in July 2013.It is not only suitable for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion mutation or exon 21 (L858R) replacement mutation, but also a second - and third-line target drug for egFR-TKIS resistance.
The global Afatinib Dimaleate market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Clinical studies have shown that afatinib dimaleate reduces the risk of both cancer progression and death by 19% compared with first-generation EGFR TKI erlotinib, and significantly improves disease control rates, quality of life, and control of cancer symptoms.Prior to the Approval in China, afatinib has been approved in more than 70 countries for the treatment of PATIENTS with EGFR mutation-positive non-small cell lung cancer, and has become the preferred egFR-targeting drug in many countries.In addition, the drug was approved in 2016 by the US FDA and the European Union respectively for patients with advanced lung squamous cell carcinoma whose disease worsens during or after platinum-based chemotherapy.At present, the drug has been included in the medical insurance in China, and it can be expected that the market size of this product will gradually expand in the future.
This report aims to provide a comprehensive presentation of the global market for Afatinib Dimaleate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Afatinib Dimaleate.
Report Scope
The Afatinib Dimaleate market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Afatinib Dimaleate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Afatinib Dimaleate companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer Ingelheim Pharmaceuticals
APExBIO Technology LLC
Carbosynth Ltd
Biorbyt
Cayman Chemical Company
Target Molecule Corp.
Frontier Specialty Chemicals
Combi-Blocks
Selleck Chemicals
AvaChem Scientific
Advanced ChemBlocks Inc
Glpbio
Nanjing Xize Pharmaceutical Technology Co., Ltd
Shandong Haiwo Biotechnology Co., Ltd
J&K Scientific
Shanghai McLin Biochemical Technology Co., Ltd
Beijing Sjar Technology Development Co., Ltd.
Beijing Wokai Biotechnology Co., Ltd
Ningbo Zhenlei Chemical Co., Ltd.
Beijing Mreda Technology Co., Ltd
MedBio Pharmaceutical Technology Inc
Shanghai Dibai Biotechnology Co., Ltd
Segment by Type
20 mg
30 mg
40 mg
Segment by Application
Treatment of EGFR Mutated Non-Small Cell Lung Cancer
Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Afatinib Dimaleate companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Afatinib dimaleate is an oral molecular targeted drug developed and produced by Boehringer Ingelheim, Germany. It is a TKIs with strong and irreversible dual inhibitory effect on EGFR and HER2, and was approved by THE US FDA in July 2013.It is not only suitable for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion mutation or exon 21 (L858R) replacement mutation, but also a second - and third-line target drug for egFR-TKIS resistance.
The global Afatinib Dimaleate market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Clinical studies have shown that afatinib dimaleate reduces the risk of both cancer progression and death by 19% compared with first-generation EGFR TKI erlotinib, and significantly improves disease control rates, quality of life, and control of cancer symptoms.Prior to the Approval in China, afatinib has been approved in more than 70 countries for the treatment of PATIENTS with EGFR mutation-positive non-small cell lung cancer, and has become the preferred egFR-targeting drug in many countries.In addition, the drug was approved in 2016 by the US FDA and the European Union respectively for patients with advanced lung squamous cell carcinoma whose disease worsens during or after platinum-based chemotherapy.At present, the drug has been included in the medical insurance in China, and it can be expected that the market size of this product will gradually expand in the future.
This report aims to provide a comprehensive presentation of the global market for Afatinib Dimaleate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Afatinib Dimaleate.
Report Scope
The Afatinib Dimaleate market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Afatinib Dimaleate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Afatinib Dimaleate companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer Ingelheim Pharmaceuticals
APExBIO Technology LLC
Carbosynth Ltd
Biorbyt
Cayman Chemical Company
Target Molecule Corp.
Frontier Specialty Chemicals
Combi-Blocks
Selleck Chemicals
AvaChem Scientific
Advanced ChemBlocks Inc
Glpbio
Nanjing Xize Pharmaceutical Technology Co., Ltd
Shandong Haiwo Biotechnology Co., Ltd
J&K Scientific
Shanghai McLin Biochemical Technology Co., Ltd
Beijing Sjar Technology Development Co., Ltd.
Beijing Wokai Biotechnology Co., Ltd
Ningbo Zhenlei Chemical Co., Ltd.
Beijing Mreda Technology Co., Ltd
MedBio Pharmaceutical Technology Inc
Shanghai Dibai Biotechnology Co., Ltd
Segment by Type
20 mg
30 mg
40 mg
Segment by Application
Treatment of EGFR Mutated Non-Small Cell Lung Cancer
Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Afatinib Dimaleate companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Afatinib Dimaleate Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 20 mg
1.2.3 30 mg
1.2.4 40 mg
1.3 Market by Application
1.3.1 Global Afatinib Dimaleate Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Treatment of EGFR Mutated Non-Small Cell Lung Cancer
1.3.3 Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Afatinib Dimaleate Market Perspective (2019-2030)
2.2 Afatinib Dimaleate Growth Trends by Region
2.2.1 Global Afatinib Dimaleate Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Afatinib Dimaleate Historic Market Size by Region (2019-2024)
2.2.3 Afatinib Dimaleate Forecasted Market Size by Region (2025-2030)
2.3 Afatinib Dimaleate Market Dynamics
2.3.1 Afatinib Dimaleate Industry Trends
2.3.2 Afatinib Dimaleate Market Drivers
2.3.3 Afatinib Dimaleate Market Challenges
2.3.4 Afatinib Dimaleate Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Afatinib Dimaleate Players by Revenue
3.1.1 Global Top Afatinib Dimaleate Players by Revenue (2019-2024)
3.1.2 Global Afatinib Dimaleate Revenue Market Share by Players (2019-2024)
3.2 Global Afatinib Dimaleate Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Afatinib Dimaleate Revenue
3.4 Global Afatinib Dimaleate Market Concentration Ratio
3.4.1 Global Afatinib Dimaleate Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Afatinib Dimaleate Revenue in 2023
3.5 Afatinib Dimaleate Key Players Head office and Area Served
3.6 Key Players Afatinib Dimaleate Product Solution and Service
3.7 Date of Enter into Afatinib Dimaleate Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Afatinib Dimaleate Breakdown Data by Type
4.1 Global Afatinib Dimaleate Historic Market Size by Type (2019-2024)
4.2 Global Afatinib Dimaleate Forecasted Market Size by Type (2025-2030)
5 Afatinib Dimaleate Breakdown Data by Application
5.1 Global Afatinib Dimaleate Historic Market Size by Application (2019-2024)
5.2 Global Afatinib Dimaleate Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Afatinib Dimaleate Market Size (2019-2030)
6.2 North America Afatinib Dimaleate Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Afatinib Dimaleate Market Size by Country (2019-2024)
6.4 North America Afatinib Dimaleate Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Afatinib Dimaleate Market Size (2019-2030)
7.2 Europe Afatinib Dimaleate Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Afatinib Dimaleate Market Size by Country (2019-2024)
7.4 Europe Afatinib Dimaleate Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Afatinib Dimaleate Market Size (2019-2030)
8.2 Asia-Pacific Afatinib Dimaleate Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Afatinib Dimaleate Market Size by Region (2019-2024)
8.4 Asia-Pacific Afatinib Dimaleate Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Afatinib Dimaleate Market Size (2019-2030)
9.2 Latin America Afatinib Dimaleate Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Afatinib Dimaleate Market Size by Country (2019-2024)
9.4 Latin America Afatinib Dimaleate Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Afatinib Dimaleate Market Size (2019-2030)
10.2 Middle East & Africa Afatinib Dimaleate Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Afatinib Dimaleate Market Size by Country (2019-2024)
10.4 Middle East & Africa Afatinib Dimaleate Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim Pharmaceuticals
11.1.1 Boehringer Ingelheim Pharmaceuticals Company Detail
11.1.2 Boehringer Ingelheim Pharmaceuticals Business Overview
11.1.3 Boehringer Ingelheim Pharmaceuticals Afatinib Dimaleate Introduction
11.1.4 Boehringer Ingelheim Pharmaceuticals Revenue in Afatinib Dimaleate Business (2019-2024)
11.1.5 Boehringer Ingelheim Pharmaceuticals Recent Development
11.2 APExBIO Technology LLC
11.2.1 APExBIO Technology LLC Company Detail
11.2.2 APExBIO Technology LLC Business Overview
11.2.3 APExBIO Technology LLC Afatinib Dimaleate Introduction
11.2.4 APExBIO Technology LLC Revenue in Afatinib Dimaleate Business (2019-2024)
11.2.5 APExBIO Technology LLC Recent Development
11.3 Carbosynth Ltd
11.3.1 Carbosynth Ltd Company Detail
11.3.2 Carbosynth Ltd Business Overview
11.3.3 Carbosynth Ltd Afatinib Dimaleate Introduction
11.3.4 Carbosynth Ltd Revenue in Afatinib Dimaleate Business (2019-2024)
11.3.5 Carbosynth Ltd Recent Development
11.4 Biorbyt
11.4.1 Biorbyt Company Detail
11.4.2 Biorbyt Business Overview
11.4.3 Biorbyt Afatinib Dimaleate Introduction
11.4.4 Biorbyt Revenue in Afatinib Dimaleate Business (2019-2024)
11.4.5 Biorbyt Recent Development
11.5 Cayman Chemical Company
11.5.1 Cayman Chemical Company Company Detail
11.5.2 Cayman Chemical Company Business Overview
11.5.3 Cayman Chemical Company Afatinib Dimaleate Introduction
11.5.4 Cayman Chemical Company Revenue in Afatinib Dimaleate Business (2019-2024)
11.5.5 Cayman Chemical Company Recent Development
11.6 Target Molecule Corp.
11.6.1 Target Molecule Corp. Company Detail
11.6.2 Target Molecule Corp. Business Overview
11.6.3 Target Molecule Corp. Afatinib Dimaleate Introduction
11.6.4 Target Molecule Corp. Revenue in Afatinib Dimaleate Business (2019-2024)
11.6.5 Target Molecule Corp. Recent Development
11.7 Frontier Specialty Chemicals
11.7.1 Frontier Specialty Chemicals Company Detail
11.7.2 Frontier Specialty Chemicals Business Overview
11.7.3 Frontier Specialty Chemicals Afatinib Dimaleate Introduction
11.7.4 Frontier Specialty Chemicals Revenue in Afatinib Dimaleate Business (2019-2024)
11.7.5 Frontier Specialty Chemicals Recent Development
11.8 Combi-Blocks
11.8.1 Combi-Blocks Company Detail
11.8.2 Combi-Blocks Business Overview
11.8.3 Combi-Blocks Afatinib Dimaleate Introduction
11.8.4 Combi-Blocks Revenue in Afatinib Dimaleate Business (2019-2024)
11.8.5 Combi-Blocks Recent Development
11.9 Selleck Chemicals
11.9.1 Selleck Chemicals Company Detail
11.9.2 Selleck Chemicals Business Overview
11.9.3 Selleck Chemicals Afatinib Dimaleate Introduction
11.9.4 Selleck Chemicals Revenue in Afatinib Dimaleate Business (2019-2024)
11.9.5 Selleck Chemicals Recent Development
11.10 AvaChem Scientific
11.10.1 AvaChem Scientific Company Detail
11.10.2 AvaChem Scientific Business Overview
11.10.3 AvaChem Scientific Afatinib Dimaleate Introduction
11.10.4 AvaChem Scientific Revenue in Afatinib Dimaleate Business (2019-2024)
11.10.5 AvaChem Scientific Recent Development
11.11 Advanced ChemBlocks Inc
11.11.1 Advanced ChemBlocks Inc Company Detail
11.11.2 Advanced ChemBlocks Inc Business Overview
11.11.3 Advanced ChemBlocks Inc Afatinib Dimaleate Introduction
11.11.4 Advanced ChemBlocks Inc Revenue in Afatinib Dimaleate Business (2019-2024)
11.11.5 Advanced ChemBlocks Inc Recent Development
11.12 Glpbio
11.12.1 Glpbio Company Detail
11.12.2 Glpbio Business Overview
11.12.3 Glpbio Afatinib Dimaleate Introduction
11.12.4 Glpbio Revenue in Afatinib Dimaleate Business (2019-2024)
11.12.5 Glpbio Recent Development
11.13 Nanjing Xize Pharmaceutical Technology Co., Ltd
11.13.1 Nanjing Xize Pharmaceutical Technology Co., Ltd Company Detail
11.13.2 Nanjing Xize Pharmaceutical Technology Co., Ltd Business Overview
11.13.3 Nanjing Xize Pharmaceutical Technology Co., Ltd Afatinib Dimaleate Introduction
11.13.4 Nanjing Xize Pharmaceutical Technology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024)
11.13.5 Nanjing Xize Pharmaceutical Technology Co., Ltd Recent Development
11.14 Shandong Haiwo Biotechnology Co., Ltd
11.14.1 Shandong Haiwo Biotechnology Co., Ltd Company Detail
11.14.2 Shandong Haiwo Biotechnology Co., Ltd Business Overview
11.14.3 Shandong Haiwo Biotechnology Co., Ltd Afatinib Dimaleate Introduction
11.14.4 Shandong Haiwo Biotechnology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024)
11.14.5 Shandong Haiwo Biotechnology Co., Ltd Recent Development
11.15 J&K Scientific
11.15.1 J&K Scientific Company Detail
11.15.2 J&K Scientific Business Overview
11.15.3 J&K Scientific Afatinib Dimaleate Introduction
11.15.4 J&K Scientific Revenue in Afatinib Dimaleate Business (2019-2024)
11.15.5 J&K Scientific Recent Development
11.16 Shanghai McLin Biochemical Technology Co., Ltd
11.16.1 Shanghai McLin Biochemical Technology Co., Ltd Company Detail
11.16.2 Shanghai McLin Biochemical Technology Co., Ltd Business Overview
11.16.3 Shanghai McLin Biochemical Technology Co., Ltd Afatinib Dimaleate Introduction
11.16.4 Shanghai McLin Biochemical Technology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024)
11.16.5 Shanghai McLin Biochemical Technology Co., Ltd Recent Development
11.17 Beijing Sjar Technology Development Co., Ltd.
11.17.1 Beijing Sjar Technology Development Co., Ltd. Company Detail
11.17.2 Beijing Sjar Technology Development Co., Ltd. Business Overview
11.17.3 Beijing Sjar Technology Development Co., Ltd. Afatinib Dimaleate Introduction
11.17.4 Beijing Sjar Technology Development Co., Ltd. Revenue in Afatinib Dimaleate Business (2019-2024)
11.17.5 Beijing Sjar Technology Development Co., Ltd. Recent Development
11.18 Beijing Wokai Biotechnology Co., Ltd
11.18.1 Beijing Wokai Biotechnology Co., Ltd Company Detail
11.18.2 Beijing Wokai Biotechnology Co., Ltd Business Overview
11.18.3 Beijing Wokai Biotechnology Co., Ltd Afatinib Dimaleate Introduction
11.18.4 Beijing Wokai Biotechnology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024)
11.18.5 Beijing Wokai Biotechnology Co., Ltd Recent Development
11.19 Ningbo Zhenlei Chemical Co., Ltd.
11.19.1 Ningbo Zhenlei Chemical Co., Ltd. Company Detail
11.19.2 Ningbo Zhenlei Chemical Co., Ltd. Business Overview
11.19.3 Ningbo Zhenlei Chemical Co., Ltd. Afatinib Dimaleate Introduction
11.19.4 Ningbo Zhenlei Chemical Co., Ltd. Revenue in Afatinib Dimaleate Business (2019-2024)
11.19.5 Ningbo Zhenlei Chemical Co., Ltd. Recent Development
11.20 Beijing Mreda Technology Co., Ltd
11.20.1 Beijing Mreda Technology Co., Ltd Company Detail
11.20.2 Beijing Mreda Technology Co., Ltd Business Overview
11.20.3 Beijing Mreda Technology Co., Ltd Afatinib Dimaleate Introduction
11.20.4 Beijing Mreda Technology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024)
11.20.5 Beijing Mreda Technology Co., Ltd Recent Development
11.21 MedBio Pharmaceutical Technology Inc
11.21.1 MedBio Pharmaceutical Technology Inc Company Detail
11.21.2 MedBio Pharmaceutical Technology Inc Business Overview
11.21.3 MedBio Pharmaceutical Technology Inc Afatinib Dimaleate Introduction
11.21.4 MedBio Pharmaceutical Technology Inc Revenue in Afatinib Dimaleate Business (2019-2024)
11.21.5 MedBio Pharmaceutical Technology Inc Recent Development
11.22 Shanghai Dibai Biotechnology Co., Ltd
11.22.1 Shanghai Dibai Biotechnology Co., Ltd Company Detail
11.22.2 Shanghai Dibai Biotechnology Co., Ltd Business Overview
11.22.3 Shanghai Dibai Biotechnology Co., Ltd Afatinib Dimaleate Introduction
11.22.4 Shanghai Dibai Biotechnology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024)
11.22.5 Shanghai Dibai Biotechnology Co., Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Afatinib Dimaleate Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of 20 mg
Table 3. Key Players of 30 mg
Table 4. Key Players of 40 mg
Table 5. Global Afatinib Dimaleate Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Afatinib Dimaleate Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Afatinib Dimaleate Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Afatinib Dimaleate Market Share by Region (2019-2024)
Table 9. Global Afatinib Dimaleate Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Afatinib Dimaleate Market Share by Region (2025-2030)
Table 11. Afatinib Dimaleate Market Trends
Table 12. Afatinib Dimaleate Market Drivers
Table 13. Afatinib Dimaleate Market Challenges
Table 14. Afatinib Dimaleate Market Restraints
Table 15. Global Afatinib Dimaleate Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Afatinib Dimaleate Market Share by Players (2019-2024)
Table 17. Global Top Afatinib Dimaleate Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Afatinib Dimaleate as of 2023)
Table 18. Ranking of Global Top Afatinib Dimaleate Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Afatinib Dimaleate Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Afatinib Dimaleate Product Solution and Service
Table 22. Date of Enter into Afatinib Dimaleate Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Afatinib Dimaleate Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Afatinib Dimaleate Revenue Market Share by Type (2019-2024)
Table 26. Global Afatinib Dimaleate Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Afatinib Dimaleate Revenue Market Share by Type (2025-2030)
Table 28. Global Afatinib Dimaleate Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Afatinib Dimaleate Revenue Market Share by Application (2019-2024)
Table 30. Global Afatinib Dimaleate Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Afatinib Dimaleate Revenue Market Share by Application (2025-2030)
Table 32. North America Afatinib Dimaleate Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Afatinib Dimaleate Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Afatinib Dimaleate Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Afatinib Dimaleate Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Afatinib Dimaleate Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Afatinib Dimaleate Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Afatinib Dimaleate Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Afatinib Dimaleate Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Afatinib Dimaleate Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Afatinib Dimaleate Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Afatinib Dimaleate Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Afatinib Dimaleate Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Afatinib Dimaleate Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Afatinib Dimaleate Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Afatinib Dimaleate Market Size by Country (2025-2030) & (US$ Million)
Table 47. Boehringer Ingelheim Pharmaceuticals Company Detail
Table 48. Boehringer Ingelheim Pharmaceuticals Business Overview
Table 49. Boehringer Ingelheim Pharmaceuticals Afatinib Dimaleate Product
Table 50. Boehringer Ingelheim Pharmaceuticals Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 51. Boehringer Ingelheim Pharmaceuticals Recent Development
Table 52. APExBIO Technology LLC Company Detail
Table 53. APExBIO Technology LLC Business Overview
Table 54. APExBIO Technology LLC Afatinib Dimaleate Product
Table 55. APExBIO Technology LLC Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 56. APExBIO Technology LLC Recent Development
Table 57. Carbosynth Ltd Company Detail
Table 58. Carbosynth Ltd Business Overview
Table 59. Carbosynth Ltd Afatinib Dimaleate Product
Table 60. Carbosynth Ltd Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 61. Carbosynth Ltd Recent Development
Table 62. Biorbyt Company Detail
Table 63. Biorbyt Business Overview
Table 64. Biorbyt Afatinib Dimaleate Product
Table 65. Biorbyt Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 66. Biorbyt Recent Development
Table 67. Cayman Chemical Company Company Detail
Table 68. Cayman Chemical Company Business Overview
Table 69. Cayman Chemical Company Afatinib Dimaleate Product
Table 70. Cayman Chemical Company Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 71. Cayman Chemical Company Recent Development
Table 72. Target Molecule Corp. Company Detail
Table 73. Target Molecule Corp. Business Overview
Table 74. Target Molecule Corp. Afatinib Dimaleate Product
Table 75. Target Molecule Corp. Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 76. Target Molecule Corp. Recent Development
Table 77. Frontier Specialty Chemicals Company Detail
Table 78. Frontier Specialty Chemicals Business Overview
Table 79. Frontier Specialty Chemicals Afatinib Dimaleate Product
Table 80. Frontier Specialty Chemicals Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 81. Frontier Specialty Chemicals Recent Development
Table 82. Combi-Blocks Company Detail
Table 83. Combi-Blocks Business Overview
Table 84. Combi-Blocks Afatinib Dimaleate Product
Table 85. Combi-Blocks Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 86. Combi-Blocks Recent Development
Table 87. Selleck Chemicals Company Detail
Table 88. Selleck Chemicals Business Overview
Table 89. Selleck Chemicals Afatinib Dimaleate Product
Table 90. Selleck Chemicals Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 91. Selleck Chemicals Recent Development
Table 92. AvaChem Scientific Company Detail
Table 93. AvaChem Scientific Business Overview
Table 94. AvaChem Scientific Afatinib Dimaleate Product
Table 95. AvaChem Scientific Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 96. AvaChem Scientific Recent Development
Table 97. Advanced ChemBlocks Inc Company Detail
Table 98. Advanced ChemBlocks Inc Business Overview
Table 99. Advanced ChemBlocks Inc Afatinib Dimaleate Product
Table 100. Advanced ChemBlocks Inc Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 101. Advanced ChemBlocks Inc Recent Development
Table 102. Glpbio Company Detail
Table 103. Glpbio Business Overview
Table 104. Glpbio Afatinib Dimaleate Product
Table 105. Glpbio Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 106. Glpbio Recent Development
Table 107. Nanjing Xize Pharmaceutical Technology Co., Ltd Company Detail
Table 108. Nanjing Xize Pharmaceutical Technology Co., Ltd Business Overview
Table 109. Nanjing Xize Pharmaceutical Technology Co., Ltd Afatinib Dimaleate Product
Table 110. Nanjing Xize Pharmaceutical Technology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 111. Nanjing Xize Pharmaceutical Technology Co., Ltd Recent Development
Table 112. Shandong Haiwo Biotechnology Co., Ltd Company Detail
Table 113. Shandong Haiwo Biotechnology Co., Ltd Business Overview
Table 114. Shandong Haiwo Biotechnology Co., Ltd Afatinib Dimaleate Product
Table 115. Shandong Haiwo Biotechnology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 116. Shandong Haiwo Biotechnology Co., Ltd Recent Development
Table 117. J&K Scientific Company Detail
Table 118. J&K Scientific Business Overview
Table 119. J&K Scientific Afatinib Dimaleate Product
Table 120. J&K Scientific Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 121. J&K Scientific Recent Development
Table 122. Shanghai McLin Biochemical Technology Co., Ltd Company Detail
Table 123. Shanghai McLin Biochemical Technology Co., Ltd Business Overview
Table 124. Shanghai McLin Biochemical Technology Co., Ltd Afatinib Dimaleate Product
Table 125. Shanghai McLin Biochemical Technology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 126. Shanghai McLin Biochemical Technology Co., Ltd Recent Development
Table 127. Beijing Sjar Technology Development Co., Ltd. Company Detail
Table 128. Beijing Sjar Technology Development Co., Ltd. Business Overview
Table 129. Beijing Sjar Technology Development Co., Ltd. Afatinib Dimaleate Product
Table 130. Beijing Sjar Technology Development Co., Ltd. Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 131. Beijing Sjar Technology Development Co., Ltd. Recent Development
Table 132. Beijing Wokai Biotechnology Co., Ltd Company Detail
Table 133. Beijing Wokai Biotechnology Co., Ltd Business Overview
Table 134. Beijing Wokai Biotechnology Co., Ltd Afatinib Dimaleate Product
Table 135. Beijing Wokai Biotechnology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 136. Beijing Wokai Biotechnology Co., Ltd Recent Development
Table 137. Ningbo Zhenlei Chemical Co., Ltd. Company Detail
Table 138. Ningbo Zhenlei Chemical Co., Ltd. Business Overview
Table 139. Ningbo Zhenlei Chemical Co., Ltd. Afatinib Dimaleate Product
Table 140. Ningbo Zhenlei Chemical Co., Ltd. Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 141. Ningbo Zhenlei Chemical Co., Ltd. Recent Development
Table 142. Beijing Mreda Technology Co., Ltd Company Detail
Table 143. Beijing Mreda Technology Co., Ltd Business Overview
Table 144. Beijing Mreda Technology Co., Ltd Afatinib Dimaleate Product
Table 145. Beijing Mreda Technology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 146. Beijing Mreda Technology Co., Ltd Recent Development
Table 147. MedBio Pharmaceutical Technology Inc Company Detail
Table 148. MedBio Pharmaceutical Technology Inc Business Overview
Table 149. MedBio Pharmaceutical Technology Inc Afatinib Dimaleate Product
Table 150. MedBio Pharmaceutical Technology Inc Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 151. MedBio Pharmaceutical Technology Inc Recent Development
Table 152. Shanghai Dibai Biotechnology Co., Ltd Company Detail
Table 153. Shanghai Dibai Biotechnology Co., Ltd Business Overview
Table 154. Shanghai Dibai Biotechnology Co., Ltd Afatinib Dimaleate Product
Table 155. Shanghai Dibai Biotechnology Co., Ltd Revenue in Afatinib Dimaleate Business (2019-2024) & (US$ Million)
Table 156. Shanghai Dibai Biotechnology Co., Ltd Recent Development
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Afatinib Dimaleate Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Afatinib Dimaleate Market Share by Type: 2023 VS 2030
Figure 3. 20 mg Features
Figure 4. 30 mg Features
Figure 5. 40 mg Features
Figure 6. Global Afatinib Dimaleate Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Afatinib Dimaleate Market Share by Application: 2023 VS 2030
Figure 8. Treatment of EGFR Mutated Non-Small Cell Lung Cancer Case Studies
Figure 9. Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically Case Studies
Figure 10. Afatinib Dimaleate Report Years Considered
Figure 11. Global Afatinib Dimaleate Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Afatinib Dimaleate Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Afatinib Dimaleate Market Share by Region: 2023 VS 2030
Figure 14. Global Afatinib Dimaleate Market Share by Players in 2023
Figure 15. Global Top Afatinib Dimaleate Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Afatinib Dimaleate as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Afatinib Dimaleate Revenue in 2023
Figure 17. North America Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Afatinib Dimaleate Market Share by Country (2019-2030)
Figure 19. United States Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Afatinib Dimaleate Market Share by Country (2019-2030)
Figure 23. Germany Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Afatinib Dimaleate Market Share by Region (2019-2030)
Figure 31. China Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Afatinib Dimaleate Market Share by Country (2019-2030)
Figure 39. Mexico Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Afatinib Dimaleate Market Share by Country (2019-2030)
Figure 43. Turkey Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Afatinib Dimaleate Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Boehringer Ingelheim Pharmaceuticals Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 46. APExBIO Technology LLC Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 47. Carbosynth Ltd Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 48. Biorbyt Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 49. Cayman Chemical Company Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 50. Target Molecule Corp. Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 51. Frontier Specialty Chemicals Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 52. Combi-Blocks Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 53. Selleck Chemicals Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 54. AvaChem Scientific Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 55. Advanced ChemBlocks Inc Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 56. Glpbio Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 57. Nanjing Xize Pharmaceutical Technology Co., Ltd Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 58. Shandong Haiwo Biotechnology Co., Ltd Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 59. J&K Scientific Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 60. Shanghai McLin Biochemical Technology Co., Ltd Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 61. Beijing Sjar Technology Development Co., Ltd. Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 62. Beijing Wokai Biotechnology Co., Ltd Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 63. Ningbo Zhenlei Chemical Co., Ltd. Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 64. Beijing Mreda Technology Co., Ltd Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 65. MedBio Pharmaceutical Technology Inc Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 66. Shanghai Dibai Biotechnology Co., Ltd Revenue Growth Rate in Afatinib Dimaleate Business (2019-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
